SAGE Orthopaedics   /     AJSM August 2024 Podcast: Fresh Osteochondral Allograft Transplantation of the Capitellum for the Treatment of Osteochondritis Dissecans

Description

Osteochondritis dissecans (OCD) of the humeral capitellum is a rare and challenging condition to treat. Several surgical options exist, but in the last few years, the pendulum has swung from debridement and microfracture to restoration of the articular surface. Osteochondral autografts from the rib and knee have been described, but donor-site morbidity is a concern.   In conclusion, FOCAT is an excellent option for treating OCD lesions of the humeral capitellum. Excellent outcomes and high return-to-sport rates were observed, with midterm follow-up showing no graft failures. FOCAT eliminates donor-site morbidity.     Click here to read the article.

Subtitle
Osteochondritis dissecans (OCD) of the humeral capitellum is a rare and challenging condition to treat. Several surgical options exist, but in the last few years, the pendulum has swung from debridement and microfracture to restoration of the...
Duration
22:44
Publishing date
2024-08-26 13:23
Link
http://sageorthopaedics.sage-publications.libsynpro.com/ajsm-august-2024-podcast-fresh-osteochondral-allograft-transplantation-of-the-capitellum-for-the-treatment-of-osteochondritis-dissecans
Contributors
Enclosures
https://traffic.libsyn.com/secure/sageorthopaedics/AJSM_52_10.mp3?dest-id=196444
audio/mpeg

Shownotes

Osteochondritis dissecans (OCD) of the humeral capitellum is a rare and challenging condition to treat. Several surgical options exist, but in the last few years, the pendulum has swung from debridement and microfracture to restoration of the articular surface. Osteochondral autografts from the rib and knee have been described, but donor-site morbidity is a concern.   In conclusion, FOCAT is an excellent option for treating OCD lesions of the humeral capitellum. Excellent outcomes and high return-to-sport rates were observed, with midterm follow-up showing no graft failures. FOCAT eliminates donor-site morbidity.     Click here to read the article.